CN103479763B - 一种治疗临界高血压的中药组合物及其制备方法 - Google Patents
一种治疗临界高血压的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN103479763B CN103479763B CN201310425416.3A CN201310425416A CN103479763B CN 103479763 B CN103479763 B CN 103479763B CN 201310425416 A CN201310425416 A CN 201310425416A CN 103479763 B CN103479763 B CN 103479763B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- herba
- active component
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 70
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 83
- 239000012567 medical material Substances 0.000 claims description 32
- 238000000605 extraction Methods 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 9
- 238000005325 percolation Methods 0.000 claims description 7
- 241000025505 Pyrrosia Species 0.000 claims description 4
- -1 filters Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 241000195974 Selaginella Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 7
- 240000001659 Oldenlandia diffusa Species 0.000 abstract description 3
- 240000003146 Lobelia chinensis Species 0.000 abstract description 2
- 241001116757 Pyrrosia lingua Species 0.000 abstract description 2
- 241000967218 Selaginella tamariscina Species 0.000 abstract description 2
- 241000175995 Dichondra Species 0.000 abstract 1
- 230000002250 progressing effect Effects 0.000 abstract 1
- 235000015398 thunder god vine Nutrition 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 description 21
- 230000035487 diastolic blood pressure Effects 0.000 description 17
- 239000008187 granular material Substances 0.000 description 15
- 206010062717 Increased upper airway secretion Diseases 0.000 description 13
- 208000026435 phlegm Diseases 0.000 description 13
- 239000002775 capsule Substances 0.000 description 11
- 230000035488 systolic blood pressure Effects 0.000 description 10
- 239000003172 expectorant agent Substances 0.000 description 9
- 230000003419 expectorant effect Effects 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 239000006188 syrup Substances 0.000 description 8
- 235000020357 syrup Nutrition 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000001631 hypertensive effect Effects 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000015091 medicinal tea Nutrition 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010000358 Accelerated hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000506964 Dichondra repens Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 241000236488 Lepra Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000607292 Maguireothamnus speciosus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001237997 Pyrrosia petiolosa Species 0.000 description 1
- 241001237996 Pyrrosia sheareri Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 241000927895 Selaginella pulvinata Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
有效例数 | 痊愈例数 | 有效率% | |
治疗组 | 47 | 36 | 76.6%△ |
对照组 | 48 | 6 | 12.5% |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310425416.3A CN103479763B (zh) | 2013-09-18 | 2013-09-18 | 一种治疗临界高血压的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310425416.3A CN103479763B (zh) | 2013-09-18 | 2013-09-18 | 一种治疗临界高血压的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103479763A CN103479763A (zh) | 2014-01-01 |
CN103479763B true CN103479763B (zh) | 2014-10-22 |
Family
ID=49820577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310425416.3A Expired - Fee Related CN103479763B (zh) | 2013-09-18 | 2013-09-18 | 一种治疗临界高血压的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103479763B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104623108A (zh) * | 2015-02-28 | 2015-05-20 | 陈彬 | 一种治疗痰湿中阻型高血压的中药组合物及其制备方法 |
CN113082076A (zh) * | 2021-04-16 | 2021-07-09 | 江西农业大学 | 一种含白藜芦醇的饲料添加剂、制备方法及其在蛋鸡脂肪肝防治中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1061867C (zh) * | 1996-09-10 | 2001-02-14 | 吴荫福 | 消瘤解毒水剂 |
CN1160099C (zh) * | 2002-02-27 | 2004-08-04 | 李东振 | 一种抗癌胶囊及制作工艺 |
CN101254269B (zh) * | 2008-04-18 | 2011-06-29 | 翁敬周 | 一种治疗癌症的药物组合物、其制备方法及其用途 |
-
2013
- 2013-09-18 CN CN201310425416.3A patent/CN103479763B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103479763A (zh) | 2014-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102716459B (zh) | 一种治疗老年轻度认知障碍的中药组合物及其制备方法 | |
CN103479763B (zh) | 一种治疗临界高血压的中药组合物及其制备方法 | |
CN104586952A (zh) | 岩黄连中药组合物在制备治疗心脏病药物的应用 | |
CN103202956A (zh) | 一种降血压养生保健药酒 | |
CN104857366A (zh) | 一种神经外科术前干预药物组合物及其应用 | |
CN104984180A (zh) | 一种治疗痛风的中药组合物及其制备方法 | |
CN1284593C (zh) | 一种治疗过敏性紫癜的药 | |
CN104147346A (zh) | 一种治疗冠脉弥漫性病变心绞痛的中药复方 | |
CN102552715B (zh) | 中药组合物、含有该组合物的药物及其制备方法 | |
CN102068520A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN106620253B (zh) | 一种治疗缓慢性心律失常的中药组合物 | |
CN102579804B (zh) | 一种治疗心绞痛的中药 | |
CN101518630A (zh) | 一种抗痛风的中药组合物及其制备方法 | |
CN107913315A (zh) | 一种治疗难治性高血压的中药组合物及其制备方法 | |
CN103768129A (zh) | 一种预防或治疗高血压的药物组合物 | |
CN112022977B (zh) | 治疗高血压的中药组合物及其中药制剂和应用 | |
CN102861241B (zh) | 一种治疗急性心肌梗塞的中药补气化瘀汤 | |
CN102283980B (zh) | 治疗慢性肾脏病湿热壅盛型的药物 | |
CN101879227B (zh) | 一种治疗腰椎间盘突出症的中药组合物及其制备方法 | |
CN106511903B (zh) | 辅助利尿剂治疗老年高血压、改善依从性问题的组合物 | |
CN106728828A (zh) | 一种治疗冠心病的中药制剂及其制备工艺 | |
CN105168653A (zh) | 一种用于治疗冠心病的中药组合物 | |
CN110170010A (zh) | 一种用于治疗尿频、尿急、尿失禁等症的中药组合物及其制备方法与应用 | |
CN103479915A (zh) | 一种治疗急性肾炎的中药组合物及其制备方法 | |
CN104352561A (zh) | 一种含怀牛膝的降血压用中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140101 Assignee: GUANGXI YULIN TIANDIWANG AGRICULTURE TECHNOLOGY CO.,LTD. Assignor: Feng Risheng Contract record no.: 2018450000012 Denomination of invention: Traditional Chinese medicine composition for treating borderline hypertension and preparation method thereof Granted publication date: 20141022 License type: Common License Record date: 20180424 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141022 |
|
CF01 | Termination of patent right due to non-payment of annual fee |